All In Biotech

BLA 761064 · Genentech INC

Rituxan Hycela

Rituximab, Hyaluronidase (Human Recombinant) · Subcutaneous · Endoglycosidase; CD20-directed Cytolytic Antibody

Orphan

Last checked: Nov 20, 2026Latest source record: Jun 10, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Jun 22, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,564

526 Phase 3, 340 recruiting

FAERS reports

453

159 serious, 42 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY WARNING: SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY See full prescribing information for complete boxed warning. Severe mucocutaneous reactions, some with fatal outcomes ( 5.1 ). Hepatitis B virus reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death ( 5.2 ). Progressive multifocal leukoencephalopathy resulting in death ( 5.3 ). Severe Mucocutaneous Reactions Severe, including fatal, mucocutaneous reactions can occur in patients receiving rituximab-containing products, including RITUXAN HYCELA [see Warnings and Precautions (5.1) ]. Hepatitis B Virus (HBV) Reactivation HBV reactivation can occur in patients treated with rituximab-containing products, including RITUXAN...

What it is approved for

From the label in effect Sep 23, 2026.

RITUXAN HYCELA is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with: Follicular Lymphoma (FL) ( 1.1 ) Relapsed or refractory, follicular lymphoma as a single agent Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy Non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy Diffuse Large B-cell Lymphoma (DLBCL) ( 1.2 ) Previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens Chronic Lymphocytic Leukemia (CLL) ( 1.3 ) Previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide (FC) Limitations of Use: Initiate treatment with RITUXAN HYCELA only after patients have received at least one full dose of a rituximab product by intravenous infusion. ( 1.4 , 2.1 , 5.4 ). RITUXAN HYCELA is not indicated for the treatment of non-malignant conditions. ( 1.4 ) 1.1 Follicular Lymphoma (FL) RITUXAN HYCELA is indicated for the treatment of adult patients with: Relapsed or refractory, follicular lymphoma as a single agent. Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), follicular lymphoma as a single agent after...

Mechanism: Rituximab is a monoclonal antibody that targets the CD20 antigen expressed on the surface of pre-B and mature B-lymphocytes. Upon binding to CD20, rituximab mediates B-cell lysis. Possible mechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity (ADCC). Hyaluronan is a polysaccharide found in the extracellular matrix of the subcutaneous tissue. It is depolymerized by the naturally occurring enzyme hyaluronidase. Unlike the stable structural components of the interstitial matrix, hyaluronan has a half-life of approximately 0.5...

Therapeutic areas: Hematology and blood cancers

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 22, 2017 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLetterReview
2 products under this application
  • RITUXAN HYCELA · RITUXIMAB 1400MG and 23400UNITS/11.7ML; HYALURONIDASE (HUMAN RECOMBINANT) · SOLUTION, SUBCUTANEOUS · Prescription
  • RITUXAN HYCELA · RITUXIMAB 1600MG and 26800UNITS/13.4ML; HYALURONIDASE (HUMAN RECOMBINANT) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Rituximab" as an intervention, any sponsor and status, largest first.

All 2,564 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • no adverse event88
  • off label use82
  • rash50
  • fatigue36
  • nausea35
  • pain33
  • headache28
  • dizziness27
  • pneumonia27
  • dyspnoea26
  • diarrhoea25
  • intentional product use issue25

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20152
201724
201871
201967
202073
202144
202234
202334
202459
202528
202617

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rituxan Hycela (Rituximab/Hyaluronidase,Human)

2024 spending

$736K

Beneficiaries

28

101 claims

Per beneficiary

$26,286

$540.94 per unit

View as table
YearSpending
2020$478,580
2021$755,773
2022$882,865
2023$638,068
2024$736,009

Part B: Rituxan Hycela (Rituximab/Hyaluronidase,human) · HCPCS J9311

2024 spending

$49.1M

Beneficiaries

2,622

9,453 claims

Per beneficiary

$18,717

2024 ASP limit $37.03 per unit

View as table
YearSpending
2020$97,461,481
2021$68,338,781
2022$57,526,961
2023$49,559,522
2024$49,076,761

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,599 on PubMed

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.